If a strategy has worked before, try it again. Baxter (NYSE: BAX )
has never been shy about identifying businesses that lie outside its
core operating focus and being willing to set them free. Edwards Lifesciences, Caremark, and Allegiance Healthcare (now part of Cardinal Health) were all once under the Baxter umbrella, and arguably did better on their own than they would have as parts of Baxter.
Now the company is doing it again, choosing to spin off its
biopharmaceuticals business as an independent publicly traded company.
Investors cheered the move, as it does remove some issues that were
clouding the value of the company's other operations.
Go to The Motley Fool for the full article:
Will Baxter International Inc's Split Unlock Shareholder Value?
No comments:
Post a Comment